Hollsteen
← Teradyne

Equity incl. NCI

Balance – as of period end · $M

QuartersFiscal years

$MEquity incl. NCI · Q1 2016: $2.0B · 10-Q 0001193125-16-589497 filed May 13, 2016Equity incl. NCI · Q2 2016: $1.7B · 10-Q 0001193125-16-680412 filed Aug 12, 2016Equity incl. NCI · Q3 2016: $1.8B · 10-Q 0001193125-16-765452 filed Nov 10, 2016Equity incl. NCI · Q4 2016: $1.8B · 10-K 0001193125-17-064638 filed Mar 1, 2017Equity incl. NCI · Q1 2017: $1.9B · 10-Q 0001193125-17-168243 filed May 12, 2017Equity incl. NCI · Q2 2017: $2.0B · 10-Q 0001193125-17-255654 filed Aug 11, 2017Equity incl. NCI · Q3 2017: $2.1B · 10-Q 0001193125-17-338478 filed Nov 9, 2017Equity incl. NCI · Q4 2017: $2.0B · 10-K 0001193125-18-066579 filed Mar 1, 2018Equity incl. NCI · Q1 2018: $1.9B · 10-Q 0001193125-18-160479 filed May 11, 2018Equity incl. NCI · Q2 2018: $1.7B · 10-Q 0001193125-18-245633 filed Aug 10, 2018Equity incl. NCI · Q3 2018: $1.7B · 10-Q 0001193125-18-323422 filed Nov 9, 2018Equity incl. NCI · Q4 2018: $1.5B · 10-K 0001193125-19-059974 filed Mar 1, 2019Equity incl. NCI · Q1 2019: $1.5B · 10-Q 0001193125-19-143836 filed May 10, 2019Equity incl. NCI · Q2 2019: $1.5B · 10-Q 0001193125-19-217772 filed Aug 9, 2019Equity incl. NCI · Q3 2019: $1.5B · 10-Q 0001193125-19-288119 filed Nov 8, 2019Equity incl. NCI · Q4 2019: $1.5B · 10-K 0001193125-20-058676 filed Mar 2, 2020Equity incl. NCI · Q1 2020: $1.6B · 10-Q 0001193125-20-132242 filed May 4, 2020Equity incl. NCI · Q2 2020: $1.7B · 10-Q 0001193125-20-207892 filed Aug 3, 2020Equity incl. NCI · Q3 2020: $2.0B · 10-Q 0001193125-20-283796 filed Nov 2, 2020Equity incl. NCI · Q4 2020: $2.2B · 10-K 0001193125-21-050735 filed Feb 22, 2021Equity incl. NCI · Q1 2021: $2.3B · 10-Q 0001193125-21-154707 filed May 7, 2021Equity incl. NCI · Q2 2021: $2.5B · 10-Q 0001193125-21-238886 filed Aug 6, 2021Equity incl. NCI · Q3 2021: $2.5B · 10-Q 0001193125-21-321554 filed Nov 5, 2021Equity incl. NCI · Q4 2021: $2.6B · 10-K 0001193125-22-049828 filed Feb 23, 2022Equity incl. NCI · Q1 2022: $2.5B · 10-Q 0001193125-22-143504 filed May 6, 2022Equity incl. NCI · Q2 2022: $2.3B · 10-Q 0001193125-22-213485 filed Aug 5, 2022Equity incl. NCI · Q3 2022: $2.3B · 10-Q 0001193125-22-277821 filed Nov 4, 2022Equity incl. NCI · Q4 2022: $2.5B · 10-K 0001193125-23-044711 filed Feb 22, 2023Equity incl. NCI · Q1 2023: $2.4B · 10-Q 0001193125-23-136994 filed May 5, 2023Equity incl. NCI · Q2 2023: $2.4B · 10-Q 0001193125-23-203780 filed Aug 4, 2023Equity incl. NCI · Q3 2023: $2.4B · 10-Q 0000950170-23-058679 filed Nov 3, 2023Equity incl. NCI · Q4 2023: $2.5B · 10-K 0000950170-24-018701 filed Feb 22, 2024Equity incl. NCI · Q1 2024: $2.6B · 10-Q 0000950170-24-052761 filed May 3, 2024Equity incl. NCI · Q2 2024: $2.7B · 10-Q 0000950170-24-089858 filed Aug 2, 2024Equity incl. NCI · Q3 2024: $2.9B · 10-Q 0000950170-24-119923 filed Nov 1, 2024Equity incl. NCI · Q4 2024: $2.8B · 10-K 0000950170-25-023784 filed Feb 20, 2025Equity incl. NCI · Q1 2025: $2.8B · 10-Q 0000950170-25-062503 filed May 2, 2025Equity incl. NCI · Q2 2025: $2.8B · 10-Q 0000950170-25-101248 filed Aug 1, 2025Equity incl. NCI · Q3 2025: $2.7B · 10-Q 0001193125-25-258477 filed Oct 30, 2025Equity incl. NCI · Q4 2025: $2.8B · 10-K 0001193125-26-059002 filed Feb 19, 2026Equity incl. NCI · Q1 2026: $3.1B · 10-Q 0001193125-26-201058 filed May 1, 2026Equity incl. NCI · Q2 2026: $3.5B · 10-Q 0001193125-26-327715 filed Jul 31, 20262,5373,4731,996Q1 2016Q2 2026Q3 2021
$MEquity incl. NCI · Q3 2020: $2.0B · 10-Q 0001193125-20-283796 filed Nov 2, 2020Equity incl. NCI · Q4 2020: $2.2B · 10-K 0001193125-21-050735 filed Feb 22, 2021Equity incl. NCI · Q1 2021: $2.3B · 10-Q 0001193125-21-154707 filed May 7, 2021Equity incl. NCI · Q2 2021: $2.5B · 10-Q 0001193125-21-238886 filed Aug 6, 2021Equity incl. NCI · Q3 2021: $2.5B · 10-Q 0001193125-21-321554 filed Nov 5, 2021Equity incl. NCI · Q4 2021: $2.6B · 10-K 0001193125-22-049828 filed Feb 23, 2022Equity incl. NCI · Q1 2022: $2.5B · 10-Q 0001193125-22-143504 filed May 6, 2022Equity incl. NCI · Q2 2022: $2.3B · 10-Q 0001193125-22-213485 filed Aug 5, 20222,5372,2991,994Q3 2020Q2 2022Q3 2021
Q3 2021
2,537$M
All values (42)
PeriodValue ($M)Status
Q2 20263,473reported
Q1 20263,144reported
Q4 20252,796reported
Q3 20252,717reported
Q2 20252,837reported
Q1 20252,797reported
Q4 20242,819reported
Q3 20242,903reported
Q2 20242,731reported
Q1 20242,558reported
Q4 20232,526reported
Q3 20232,441reported
Q2 20232,435reported
Q1 20232,449reported
Q4 20222,451reported
Q3 20222,254reported
Q2 20222,299reported
Q1 20222,475reported
Q4 20212,562reported
Q3 20212,537reported
Q2 20212,493reported
Q1 20212,325reported
Q4 20202,207reported
Q3 20201,994reported
Q2 20201,745reported
Q1 20201,551reported
Q4 20191,480reported
Q3 20191,483reported
Q2 20191,479reported
Q1 20191,470reported
Q4 20181,522reported
Q3 20181,668reported
Q2 20181,740reported
Q1 20181,905reported
Q4 20171,954reported
Q3 20172,110reported
Q2 20172,049reported
Q1 20171,920reported
Q4 20161,829reported
Q3 20161,782reported
Q2 20161,746reported
Q1 20161,996reported

CSV with all sources · Technical ID: equity_total

More metrics for Teradyne

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Sources & calculation
Value
$2.5B
Period
Q3 2021, ended Oct 3, 2021 · as of Oct 3, 2021 (balance as of date, not a sum)
Source
10-Q, filed Nov 5, 2021 · 0001193125-21-321554
Location
us-gaap:StockholdersEquity
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$2.5BNov 5, 202110-Q 0001193125-21-321554reported · confidence 1. · current